

Article

Extensive Structure Modification on Luteolin-Cinnamic Acid Conjugates Leading to BACE1 Inhibitors with Optimal Pharmacological Properties

De-Yang Sun, Chen Cheng, Katrin Moschke, Jian Huang and Wei-Shuo Fang

Special Issue

Development of Novel Drugs for Alzheimer's Disease

Edited by

Prof. Dr. Kamil Kuca, Prof. Dr. Tanos Celmar Costa Franca and Prof. Dr. Teodorico C. Ramalho



Article

Extensive Structure Modification on Luteolin-Cinnamic Acid Conjugates Leading to BACE1 Inhibitors with Optimal Pharmacological Properties

De-Yang Sun ¹, Chen Cheng ², Katrin Moschke ^{3,4}, Jian Huang ² and Wei-Shuo Fang ^{1,*}

¹ State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 2A Nan Wei Road, Beijing 100050, China; sdy887@126.com

² College of Life Science, Wuhan University, Wuhan 430072, Hubei, China; cccc@whu.edu.cn (C.C.); jianhuang@whu.edu.cn (J.H.)

³ German Center for Neurodegenerative Diseases (DZNE) and Munich Cluster for Systems Neurology (SyNergy), Technical University of Munich, Feodor-Lynen-Strasse 17, 81377 Munich, Germany; katrin.moschke@dzne.de

⁴ Neuroproteomics, Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany

* Correspondence: wfang@imm.ac.cn; Tel.: +86-10-6316-5229

Academic Editors: Kamil Kuca, Tanos Celmar Costa Franca and Teodorico C. Ramalho

Received: 21 November 2019; Accepted: 23 December 2019; Published: 26 December 2019



Abstract: BACE1 inhibitory conjugates derived from two natural products, luteolin (**1**) and *p*-hydroxy-cinnamic acid (**2**), were subjected to systematic structure modifications, including various positions in luteolin segment for conjugation, different linkers (length, bond variation), as well as various substitutions in cinnamic acid segment (various substituents on benzene, and replacement of benzene by heteroaromatics and cycloalkane). Optimal conjugates such as **7c** and **7k** were chosen on the basis of a series of bioassay data for further investigation.

Keywords: beta-secretase; BACE1 inhibitor; flavonoid; luteolin; cinnamic acid

1. Introduction

Alzheimer's disease (AD) is an age-dependent chronic neurodegenerative disease that is characterized by the presence of extracellular senile plaques and neurofibrillary tangles, as well as synaptic dysfunction and neuronal cell death. According to the World Health Organization (WHO), about 35.6 million people were diagnosed with dementia in 2010, and the number is projected to double every 20 years. The overall cost for dementia worldwide has been estimated at approximately 604 billion U.S. dollars [1].

Although the cause of AD remains in debate, β -amyloid cascade hypothesis ($A\beta$ hypothesis) or its modified version is the most widely accepted pathological mechanism according to genetic and pathological evidence among many mechanisms. $A\beta$, a peptide consisting of 37–43 amino acids, is proposed as aggregating into soluble oligomers and fibrils, which are toxic to neurons, causing neuronal death. Another protein, tau, can also be a causative factor independently, presumably acting downstream of $A\beta$ aggregation [2–4].

$A\beta$ is generated by the sequential endoproteolytic cleavage of amyloid precursor protein (APP), a transmembrane protein expressed in many tissues and organs, by β -secretase (BACE1, also known as β -site amyloid precursor protein cleaving enzyme 1) and γ -secretases subsequently in the brain [5].

Thus, the key enzyme BACE1 involved in the generation of A β has been regarded as an attractive AD drug target for about two decades. Many different chemotypes of BACE1 inhibitors have been developed [6]. Although some BACE1 inhibitors have advanced to clinical research, none of them have finished the phase III clinical trial due to diverse side effects and/or lack of effectiveness [7].

The failure of these clinical trials, including the most recent discontinuation of AstraZeneca/Eli Lilly's Lanabecestat in phase III clinical trial, proposed that the early intervention of AD, even without any symptoms, may be necessary for the success of the BACE1 inhibitors [8,9]. The kickoff of prevention trial with BACE1 inhibitor CNP250 represents a new trend in BACE1 inhibitor development [10].

The side effects have arisen from, at least for some of the BACE1 inhibitor drug candidates, the indiscriminately blocking of almost all functions and substrate cleavages related to BACE1 by the active site inhibitors [11].

Unlike competitive inhibitors targeting enzyme active site, non-competitive inhibitors binding to allosteric sites may selectively inhibit specific functions of an enzyme, resulting in less side effects [12].

In our previous work [13], luteolin (1) and *p*-hydroxy-cinnamic acid (2) (Figure 1) were found to simultaneously bind different parts of BACE1 protein by STD-NMR experiment [14]. We designed the conjugates to link two segments through proper linkage to improve the potency. Conjugate 3 (Figure 1) was found in our previous work as a potent, cell-permeable, and non-competitive inhibitor. In this work, an extensive modification of 3 was designed and performed to optimize it so as to find BACE inhibitors with optimal drug-like properties.




Figure 1. The structures of source compounds 1, 2, and 3.

In this paper, we first probed the different positions in flavonoid segment for conjugation of cinnamoyl segment, in order to avoid the possibly imprecise information derived from STD-NMR. After the C-7 position of flavone segment was confirmed as the optimal position among all conjugates in **Series I**, we further designed and prepared **Series II** and **Series III** compounds to optimize the linker and substituents in the cinnamoyl segment of the conjugate (Figure 2).




Figure 2. The structures of Series I, II, III compounds.


2. Results and Discussion

2.1. Design, Synthesis, and Enzyme Inhibitory Activity of Series I Compounds

Although in our previous work [13] a cell permeable BACE1 inhibitor **3** was discovered with the STD-NMR, we wished in this study to probe various positions in **1** (including 3', 4', 3, 6, and 8 positions) for direct conjugation of **2** or through ethylene glycol linkers, to avoid the possibly misleading of imprecise STD-NMR data.


In general, our designed conjugates consisted of a flavone segment, a linker, and a cinnamoyl segment. However, the synthetic routes and the choice of starting material varied to a great extent for the different conjugates.

Most luteolin analogs with hydroxyl at different positions as the flavone segment for conjugation are not commercially available, and thus were assembled from the simple starting materials aromatic aldehyde and aromatic ketone with different substituting groups, through condensation, to form chalcone structure under basic conditions, cyclized to dihydroflavone under heating conditions, and then oxidized to flavonoids with I_2 /pyridine under heating conditions (Scheme 1 and Supplementary Materials).




Scheme 1. The key synthetic steps of flavonoid structure. Reagents and conditions: (a) 20% KOH aq. ethanol, room temperature, 52–69%; (b) NaOAc, H_2O , ethanol, reflux, 26–82%; (c) I_2 , pyridine, 100 °C, 55–88%.

For the synthesis of conjugate **4j**, the flavone segment quercetin (3-OH substituted luteolin) was prepared by de-glycosylation of a natural compound rutin (auercetin-3-rutinoside). At first, per-benzylated rutin (**14**) was subjected to acid hydrolysis due to the poor stability of rutin under acidic condition. Then, ethylene glycol linker was attached to 3-OH to afford **17**. The switch of benzyl-protecting groups in **17** to methoxymethyl group in combination of the removal of temporary silyl protection of 3-O-ethylene-ol over two steps furnished **20**, which was ready for the 3-O-conjugation of cinnamoyl side chain. The switch of protecting group was intended to avoid the stringent deprotection conditions at the final stage of target compound preparation (Scheme 2).



Scheme 2. The synthetic route of target **4j** (1). Reagents and conditions: (a) BnBr, DMF, 50 °C; (b) HCl, CH₃CH₂OH, 70 °C, 84% (two steps); (c) BrCH₂CH₂OTBS, K₂CO₃, 80 °C, 53%; (d) Pd/C, 1,4-cyclohexadiene, 80 °C, 79%; (e) MOMCl, DIPEA, DCM, −20 °C, 57%; (f) CsF, DMF, 50 °C, 83%.

The terminal hydroxyl group in **20** was esterified with 4''-acetyl cinnamic acid by activated ester method, and then the acetyl in **21** was successively removed under alkaline condition and MOM groups under acidic condition to afford desired conjugates **4j** (Scheme 3).



Scheme 3. The synthetic route of target **4j** (2). Reagents and conditions: (g) 4''-acetyl cinnamic acid, EDCl, DMAP, TEA, THF, r.t. 45%; (h) K₂CO₃ in MeOH/DCM, r.t. 56%; (i) aq. 38% HCl in AcOH (*v/v* 1:15), r.t. 54%.

As seen from Table 1, the BACE1 inhibition of conjugates **4a–i** with *p*-hydroxy-cinnamic acid attached to C-3' and -4' of **1**, no matter what the linker was, and was weaker than the conjugation to

other positions of **1**. Respectively, the inhibitory effect of conjugates **4j**, **4k**, and **4l** attached to C-3, C-6, and C-8 were stronger than C-3' and -4' conjugates but weaker than the C-7 conjugate, **3**. Conjugate **4k** was weaker than the flavone segment **1** (without conjugation of **2**). The above results demonstrated the C-7 in flavone segment as the optimal conjugation position, consistent with optimization based on STD-NMR.

In addition, the acetyl group reduced inhibitory activity for all pairs of compounds (**4a** vs. **4b**, **4c** vs. **4d**, **4g** vs. **4h**), suggesting the terminal phenol group may play a role in the enzyme inhibition.




Table 1. The enzyme inhibition of **Series I** compounds.

No.	Structure	Inhibition Rate at 10 μ M (%)	IC ₅₀ (μ M)
4a		23.9 \pm 2.95	-
4b		14.8 \pm 7.35	-
4c		31.8 \pm 5.25	-
4d		39.6 \pm 12.5	-
4e		1.9 \pm 10.3	-
4f		29.4 \pm 5.5	-

Table 1. Cont.

No.	Structure	Inhibition Rate at 10 μ M (%)	IC ₅₀ (μ M)
4g		17.1 \pm 6.0	-
4h		36.0 \pm 4.2	-
4i		37.0 \pm 8.6	-
4j		59.2 \pm 6.3	6.78 \pm 0.83
4k		60.6 \pm 5.3	12.86 \pm 1.14
4l		58.4 \pm 10.2	2.47 \pm 0.17
1	-	68.6 \pm 8.9	7.02 \pm 0.85
3	-	64.8 \pm 6.0	2.19 \pm 0.34

2.2. Design, Synthesis, and Activity of **Series II** Compounds

In the previous study [13], conjugates with one to four glycols units as linkers were tested, and compound with one glycol unit (i.e., in **3**) was found to be the optimal. Here, we replaced glycol linkers by other polymethylene diols, trying to optimize the length of linker more carefully (Figure 3).





Figure 3. The design of **Series II** compounds.

For the synthesis of **Series II** compounds, the di-phenol groups on the C ring of **1** were protected with diphenylmethyldene to prepare **23**. The preparation of different hydroxyalkyl-7-luteolin could be realized by the treatment of **23** with TBS-O-hydroxyalkyl tosylate- under K_2CO_3 /acetone, except for butylene diol, in which case the reagent 4-hydroxybutyl 1-tosylate was subjected to intramolecular reaction to furnish tetrahydrofuran under the basic condition, possibly due to high reactivity of the OTs group. Thus, 4-TBS-O-butyl bromide was applied to this conjugation and the key intermediate **24** successfully prepared. After the removal of silyl protective group in **24**, the terminal hydroxyl group in **25** was esterified with 4''-acetyl cinnamic acid in the presence of EDCI to furnish **26**, which was then deprotected under acidic conditions to afford desired conjugates **5a–f** (Scheme 4).



Scheme 4. The synthetic route of target **5a–f**. Reagents and conditions: (a) dichlorodiphenylmethane, diphenyl ether, 165 °C, 70%; (b) $TsO(CH_2)_nOH$ ($n = 3, 5, 6, 8, 10$), K_2CO_3 , MeCN, reflux, 28–55%; (c) $Br(CH_2)_4OTBS$, K_2CO_3 , acetone, reflux, 12 h, 53%; (d) HF, pyridine, MeCN, r.t. overnight, 81%; (e) 4''-acetyl cinnamic acid, EDCI, DMAP, TEA, THF, r.t. 24–58%; (f) aq. 38% HCl in AcOH (v/v 1:15), r.t. 28–50%.

To explore the effect of the length of polymethylene diol linker in the conjugates, a series of conjugates **5a–f** with different length of linkers as well as **5g** without linker were prepared.

In general, the inhibitory activity of conjugates **5a–f** decreased as the length of linker increased (Table 2). Although conjugate **5a** bearing the shortest length of linker in the series was the most active, its IC_{50} was still lower than **3** bearing ethylene glycol linker. Thus, we adhered to the ethylene glycol linker in the next round of optimization.

Table 2. The enzyme inhibition of **Series II** compounds.

Compound	<i>n</i>	Inhibition Rate at 10 μ M (%)	IC_{50} (μ M)
5a	3	81.4 ± 3.8	5.26 ± 0.72
5b	4	68.1 ± 5.8	10.36 ± 1.02
5c	5	62.6 ± 6.4	20.63 ± 1.44
5d	6	42.4 ± 3.2	
5e	8	36.1 ± 2.6	
5f	10	58.2 ± 3.3	27.79 ± 1.34
5g	-	41.4 ± 4.4	
1	-	68.6 ± 8.9	7.02 ± 0.85
3	2	64.8 ± 6.0	2.19 ± 0.34

2.3. Design, Synthesis, and Activity of **Series III** Compounds

2.3.1. Design, Synthesis, and Enzyme Inhibition Activity of **Series III** Compounds

Next, we tried to optimize the other segment (i.e., cinnamoyl segment) in the conjugate, through replacing the *p*-hydroxy by other substituents on phenyl ring, and the phenyl, by heterocycles and cyclohexane (Figure 4, Table 3 and Figure 5). In addition, the ester bond between the cinnamoyl segment and the linker was replaced by amide group to make this possibly labile bond more stable (Figure 5).




Figure 4. The structure of compound **6**.

Table 3. The structure of compounds **7a–7j** and **7q**.

Compound	R =	Compound	R =
7a	H	7g	4-NO ₂
7b	2-OH	7h	4-NMe ₂
7c	3-OH	7i	4-OMe
7d	3,4-diOH	7j	4-C(CH ₃) ₃
7e	4-F	7q	4-OAc
7f	4-Cl		





Figure 5. The structure of compound 7k–7p and 8.

The general synthetic routes of **Series III** compounds were much similar to **Series II**. It should be noted that the acyl chloride method was chosen for compound **7b**, **7d**, and **7o** when the ester bond compounds were prepared (Scheme 5).



Scheme 5. The general synthetic route of **Series III** compounds. Reagents and conditions: (a). TsOCH₂CH₂OH, K₂CO₃, MeCN, reflux, 57%; (b) carboxylic acid, EDCI, DMAP, TEA, THF, 40 °C, or (b') carboxylic acid, SOCl₂, DMF, DCE, 80 °C, 2 h and Py, DCM, r.t. 4 h 35–82%; (c) aq. 38% HCl in AcOH (v/v 1:15), r.t. 31–88%.

As shown in Table 4, conjugate **7k** with pyridine in placement of phenol exhibited the most potent inhibitory activity with an IC₅₀ of 0.15 µM in the series, with an approximate 10-fold enhancement compared with the flavone segment **1** or conjugate **3**. It is worth noting that many conjugates exhibited an inhibition rate of approximately 60% at 10 µM, while possessing 50% inhibition even at low concentration (e.g., **7k**, **7l** with IC₅₀s of 0.1–0.2 µM). It was difficult to reach the maximum inhibition rate of 80–90% even at 20 µM or 50 µM. An S-curve for IC₅₀ calculation of several compounds is shown in the Supplementary Materials.

Table 4. The enzyme activity of **Series III** compounds.

Compound	Inhibition rate at 10 μ M (%)	IC ₅₀ (μ M)	Compound	Inhibition rate at 10 μ M (%)	IC ₅₀ (μ M)
7a	57.5 \pm 7.5	2.49 \pm 0.32	7q	25.7 \pm 4.6	-
7b	67.7 \pm 12.5	2.27 \pm 0.42	7k	54.4 \pm 3.5	0.15 \pm 1.01
7c	66.7 \pm 8.3	1.44 \pm 0.18	7l	59.5 \pm 7.1	0.37 \pm 0.25
7d	66.6 \pm 7.1	0.23 \pm 0.02	7m	22.2 \pm 7.1	-
7e	28.5 \pm 7.1	-	7n	55.2 \pm 7.1	3.05 \pm 0.39
7f	21.3 \pm 7.1	-	7o	51.9 \pm 1.9	-
7g	73.9 \pm 7.1	0.96 \pm 1.55	7p	56.7 \pm 4.4	4.39 \pm 0.34
7h	53.8 \pm 4.4	6.58 \pm 1.16	8	59.5 \pm 4.4	4.15 \pm 1.97
7i	28.9 \pm 4.4	-	6	20.5 \pm 4.4	-
7j	37.6 \pm 4.4	-	1	64.8 \pm 6.0	1.09 \pm 1.34
3	68.6 \pm 8.9	1.87 \pm 1.91			

The structure activity relationship (SAR) for **Series III** can be summarized as follows: (1) The hydroxy on ring B of flavone segment was necessary for activity (possibly through hydrogen bonding). The inhibitory activity of conjugates decreased obviously when the hydroxy was replaced by hydrogen or other groups (**3** vs. **6**). (2) The hydroxy on the benzene ring of cinnamoyl segment was also important. The inhibitory activity of conjugates decreased when the hydroxy was replaced by other non-polar substituents, or by methylation or esterification (**3**, **7b**, **7c**, **7d** vs. **7a**, **7i**, **7q**). However, the position and number of hydroxyls did not have a significant impact on the activity (**7b**, **7c** vs. **3**). (3) The derivatives with aromatic heterocyclic showed favorable activity, especially the compound with pyridine ring. (4) When the aromatic or heteroaromatic ring (**7k–7l**, **7n–7p**) was replaced by cyclohexyl group (**7m**), the activity decreased significantly.

2.3.2. Cytotoxicity of **Series III** Compounds

It is crucial for the BACE1 inhibitors to exert their activities at sub-toxic concentration, and thus their cytotoxicity was assessed in HEK293 cells by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT) assays (Table 5). Among the compounds, **7a**, **7h**, **7q**, **7k**, and **8** were the least cytotoxic (IC₅₀ > 100 μ M), and **7c** and **7p** were weak cytotoxic (IC₅₀ = 90 μ M). Unfortunately, there was no obvious relationship between the structures and their cytotoxicity.

Table 5. Cytotoxicity study of **Series III** compounds.

Compound	IC ₅₀ (μ M)	Compound	IC ₅₀ (μ M)
7a	>100	7q	>100
7b	15.6	7k	>100
7c	90	7l	9.51
7d	16.7	7m	14.4
7e	16.8	7n	33
7f	9.97	7o	10.3
7g	21.8	7p	90
7h	>100	5g	4.21
7i	3.94	6	28.3
7j	20.3	8	>100
3	62.4	1	39.8

2.3.3. Enzyme Inhibition in Cells

To assess the cellular BACE1 inhibitory activity of the conjugates, **7a–d**, **7i**, and **7k** were incubated in APP overexpressing HEK293 cells and their inhibition on the three main A β species A β -38, A β -40, and A β -42—the main amyloidogenic peptides produced by BACE1 cleavage of APP peptide—was measured by an ELISA-like immunoassay method. A β levels were normalized to the protein

concentration in the lysate in order to rule out differences in total cell number per well of the culture plate. Additionally, the normalized A β level was set to 100% for the DMSO-treated control.

The A β levels upon treatment of different compounds are shown in Figure 6 (A β -42) and the Supplementary Materials (A β -38 and A β -40). At the higher concentrations (10, 25, and 50 μ M), **7b–d** and **1** dose-dependently reduced A β levels. It is worth noting that **7c** showed an obvious inhibition A β -42 level at 25 μ M. However, **7i** and **7k** did not reduce A β levels, and even increased A β -42 levels.




Figure 6. The normalized A β -42 level in amyloid precursor protein (APP) overexpressing HEK293 cells after the treatment of **7a–d**, **7i**, **7k**, and luteolin compared with DMSO (100%), the known inhibitor C3 [15].

2.3.4. Enzyme Kinetics Experiment and Enzyme Selectivity

We are interested to know if the most active conjugates derived from **1** and **3** will keep or change their non-competitive mode of inhibition. The Dixon plot was used to determine the kinetics of **4l**, **7c**, and **7k** inhibiting BACE1. As shown in Figure 7, the three lines that stand for different substrate

concentration intersect on the x -axis, demonstrating that **7c** was a non-competitive inhibitor with a K_i value of 1.2 μM , and that **4l** and **7k** were in mix-competitive mode (Supplementary Materials).




Figure 7. Kinetic analysis of **7c**. The inhibitor was tested in the presence of different concentrations of substrate: 250 nM (\blacktriangle), 500 nM (\blacksquare), and 750 nM (\bullet). BACE1 (β -site amyloid precursor protein cleaving enzyme 1) inhibition was analyzed in the presence of different concentrations of sample as follows: 0.1 μM , 0.5 μM , 1.0 μM , 5.0 μM .

As BACE1 is a member of aspartyl protease family, its selective inhibition over other closely related proteases is required to avoid possible severe side effects. We measured the inhibition of **7c**, **7k**, and **8** on BACE-2 and renin, and found **7c** and **7k** showed very good selectivity (ca. 2–3 orders of magnitude) on BACE1 over BACE2 and renin (Table 6).

Table 6. The enzyme selectivity of compound **7c**, **7k**, and **8**.

Compound	BACE1 IC ₅₀ (μM)	BACE2 IC ₅₀ (μM)	Renin IC ₅₀ (μM)
7c	1.44 \pm 0.18	>100	>100
7k	0.15 \pm 1.01	>100	>100
8	4.15 \pm 1.97	>100	25.42

To assess the potential of these conjugates as CNS drug candidates, the ability to cross the BBB (blood-brain barrier) is worthy evaluation. Thus, we calculated cLogP and BBB penetration for several representative conjugates by an open source software [16]. The result (Figure S2) showed that some of them (e.g., **7k**) may have the ability to cross the BBB.

In summary, the extensive optimization of flavone-cinnamic acid conjugates revealed some more potent BACE1 inhibitors including **7c** and **7k**. On the basis of the analysis of multiple bioassay data, **7c** exhibited improved activity and weaker toxicity in cells, demonstrating an improvement from the starting point of this work, conjugate **3**. Moreover, **7c** also showed non-competitive mode of BACE1 inhibition and selectivity over other related enzymes such as BACE2 and renin, suggesting it may retain the selective inhibition of BACE1 as an allosteric inhibitor to facilitate the reduction of APP processing and spare other BACE1 functions. Combining the computational result of LogP and BBB-penetrating ability, it was demonstrated that such a conjugate may be served as a drug candidate for AD therapy, and in-depth PD (pharmacodynamic) and PK (pharmacokinetic) studies in animals are warranted.

3. Materials and Methods

3.1. Chemical Synthesis

In this part, the preparation for representative conjugates are shown. Other compounds and also the NMR and mass spectrometry (MS) data for structural characterization for all compounds are included in the Supplementary Materials.

3.1.1. General Methods

All chemicals and reagents were purchased from Beijing Innochem Science and Technology Co. Ltd. (Beijing, China), Sinopharm Chemical Reagent Co. Ltd. (Beijing, China), and thin-layer chromatography (TLC). The 200–300 mesh silica gel used for flash column chromatography was purchased from Rushan Shi Shuangbang Xincailiao Co. Ltd. (Rushan, Shandong, China). Visualization on TLC (analytical thin layer chromatography) was achieved by the use of UV light (254 and 365 nm). All solvents were purified and dried according to the standard procedures. The purification was performed on flash column chromatography. The high performance liquid chromatography (HPLC)–electrospray ionization (ESI)–mass spectrometry (MS) analysis was carried out in an Agilent 1260 Infinity HPLC system (Agilent Technologies, Waldbronn, Germany) equipped with a reversed phase 4.68 × 50 mm (1.8 µm) XDB-C18 Column and consisted of a binary solvent delivery system, an auto sampler, a column temperature controller, and a UV detector. The mass spectra were acquired by a 6120 Quadrupole LC-MS mass spectrometer (Agilent Technologies, Waldbronn, Germany) connected to the HPLC system via an ESI interface. Proton and carbon magnetic resonance spectra (¹H-NMR and ¹³C-NMR) were recorded on a Bruker BioSpin AG 300 or 400 MHz spectrometer or Varian 400, 500, or 600 MHz spectrometer. ¹H-NMR data were reported as follows: chemical shifts, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constant(s) in Hz, integration. All tested compounds **4a–l**, **5a–g**, **6**, **7a–q**, and **8** were ≥95% pure by HPLC (column C18 4.6 × 250 mm 5 µm, mobile phase: acetonitrile–water (70:30 or 80:20 or 90:10 in 10 min), flow rate 1.0 mL/min, detected at 254 nm).

3.1.2. Synthesis of Compound **4j**

7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-3,5-dihydroxy-4H-chromen-4-one (16): To a solution of rutin (610 mg, 1 mmol) in DMF (30 mL), BnBr (684 mg, 4 mmol) and K₂CO₃ (552 mg, 4 mmol) were added. The solution was stirred at 50 °C for 3 h. Water (100 mL) was added, and the solution was cooled to 0 °C for overnight. The solid **15** was collected by suction filtration and dissolved in 95% alcohol (20 mL), and hydrochloric acid (3 mL) was added. After stirring for 2 h at 70 °C, solid was precipitated in the solution. Then, compound **16** (740 mg, 84%) was collected by suction filtration after the solution was cooled to r.t.

7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-3-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-5-hydroxy-4H-chromen-4-one (17): To a solution of **16** (147 mg, 0.26 mmol) in DMF (5 mL), K₂CO₃ (54 mg, 0.39 mmol) and (2-bromoethoxy)(tert-butyl)dimethylsilane (93 mg, 0.39 mmol) were added. After stirring at 80 °C for 12 h, water (20 mL) was added and extracted with ethyl acetate (25 mL × 2). The organic layer was gathered, dried over Na₂SO₄, filtered, and concentrated in vacuo. The crude product was purified by column chromatography (PE/acetone = 10:1) to give **17** as yellow solids (101 mg, 52.7%).

3-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one (18): To a mixture of **17** (100 mg, 0.14 mmol) and Pd/C (150 mg) in THF (5 mL) and ethanol (5 mL), 1,4-cyclohexadiene (659 µL, 7 mmol) was added. After stirring at 80 °C for 12 h, the solution was concentrated in vacuo after suction filtration. The crude product was purified by column chromatography (PE/acetone/THF = 9:2:1) to give **18** as yellow solids (49 mg, 78.6%).

2-(3,4-bis(methoxymethoxy)phenyl)-3-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-5-hydroxy-7-(methoxymethoxy)-4H-chromen-4-one (19): The starting material **18** (310 mg, 0.67 mmol) was dissolved in DCM (5 mL), and MOMCl (0.18 mL, 2.16 mmol) was added at −10 °C. After 10 mins stirring, DIEA (0.44 mL, 2.16 mmol) was added slowly and the suspension heated to 0 °C. Saturated sodium bicarbonate (10 mL) was added to quench reaction after 1 h. The dichloromethane layer was separated, then the aqueous phase was extracted with dichloromethane (10 mL). The organic phase was merged, then washed with water and brine, dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by column chromatography (petroleum ether/acetone = 10:1) to give **19** as yellow solids (230 mg, 57.4%).

2-(3,4-bis(methoxymethoxy)phenyl)-5-hydroxy-3-(2-hydroxyethoxy)-7-(methoxymethoxy)-4H-chromen-4-one (20): A solution of compound **19** (230 mg, 0.39 mmol) and CsF (304 mg, 2 mmol) in dry DMF (2 mL) was heated to 100 °C for 2 h. The resulting mixture was diluted with water (5 mL) and extracted with ethyl acetate (10 mL \times 3). The organic layer was dried over Na₂SO₄, filtered, and concentrated in vacuo. The crude product was purified by column chromatography (petroleum ether/acetone = 5:1) to give **20** as yellow solid (154 mg, 83.0%).

2-((2-(3,4-bis(methoxymethoxy)phenyl)-5-hydroxy-7-(methoxymethoxy)-4-oxo-4H-chromen-3-yl)oxy)ethyl (E)-3-(4-acetoxyphenyl)acrylate (21): To a solution of 4-acetoxycinnamic acid (41 mg, 0.2 mmol) in THF (1 mL), EDCI (38 mg, 0.2 mmol), DMAP (6 mg, 0.05 mmol), and Et₃N (45 μ L, 0.3 mmol) were added. Then, **16a** (27 mg, 0.066 mmol) in THF (1 mL) was added under nitrogen. The solution was stirred at r.t. for 12 h. The organic layer was concentrated in vacuo. The residue was purified by column chromatography (petroleum ether/EtOAc = 3:1) to give **21** as white solid (24 mg, 45.0%).

2-((2-(3,4-bis(methoxymethoxy)phenyl)-5-hydroxy-7-(methoxymethoxy)-4-oxo-4H-chromen-3-yl)oxy)ethyl (E)-3-(4-hydroxyphenyl)acrylate (22): Compound **21** (24 mg, 0.036 mmol) was dissolved in a solution of CH₂Cl₂ (1 mL) and a K₂CO₃ (1.38 mg, 0.01 mmol) MeOH solution (1 mL) was added under argon at room temperature. After stirring for 12 h, the resulting mixture was concentrated in vacuo and purified by column chromatography (DCM/acetone = 30:1) to give **22** as yellow solid (12 mg, 56.2%).

2-((2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl)oxy)ethyl (E)-3-(4-hydroxyphenyl)acrylate (4j): To a solution of **22** (12 mg, 0.019 mmol) in 0.2 mL acetone, 38% HCl/AcOH (*v/v* = 1:15, 1.8 mL) mixture was added at room temperature. The solution was stirred at room temperature. After 24 h, yellow solid precipitated and the precipitate was filtered off, washed with water, and dried to give **4j** (5.1 mg, 53.5%) as yellow solid.

3.1.3. Synthesis of Compound 5a–f

Luteolin 3',4'-O-diphenylmethyldene (23): Dichlorodiphenylmethane (20 μ L, 1.1 mmol) was added to a stirred mixture of luteolin (20 mg, 0.07 mmol) in diphenyl ether (1.4 mL), and the reaction mixture was heated at 165 °C for 2.5 h. After being cooled to room temperature, the reaction solution was poured into petroleum ether (20 mL), and the precipitation was filtered and washed with petroleum ether. The filter residue was dissolved into acetone, and the resulting solution was concentrated and purified by column chromatography (petroleum ether/EtOAc = 4:1) to give **45** as yellow solid (22 mg, 70%).

7-(4-((tert-butyldimethylsilyl)oxy)butoxy)-2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-5-hydroxy-4H-chromen-4-one (24): TBSCl (452 mg, 3.0 mmol) and imidazole (204 mg, 3.0 mmol) were added to a solution of 4-bromobutanol (300 mg, 2.0 mmol) in DMF (3 mL) at room temperature. After stirring overnight, the resulting mixture was poured into ice-water, and extracted with EtOAc. The organic layer was washed with saturated aqueous NaHCO₃ and NaCl successively, dried over Na₂SO₄, filtered, and concentrated in vacuo to give Br(CH₂)₄OTBS crude. The crude was dissolved in acetone (3 mL), then **23** (225 mg, 0.5 mmol) and K₂CO₃ (276 mg, 2 mmol) were added. The reaction mixture was then refluxed overnight and concentrated in vacuo. The residue was purified by column chromatography (petroleum ether/acetone = 7:1) to give **24** as yellow solid (136 mg, 42.8%).

2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-5-hydroxy-7-(3-hydroxypropoxy)-4H-chromen-4-one (25a): Potassium carbonate (143 mg, 1.0 mmol) was added to a solution of **23** (315 mg, 0.7 mmol) and TsO(CH₂)₃OH (230 mg, 1.0 mmol) in CH₃CN (4 mL) at room temperature. The reaction mixture was then refluxed overnight. The resulting mixture was poured into ice-water, adjusted to neutral pH with aqueous HCl (5%), and extracted with EtOAc. The organic layer was washed with brine, dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by column chromatography (petroleum ether/acetone = 5:1) to give **25a** as yellow solid (218 mg, 34.2%).

2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-5-hydroxy-7-((5-hydroxypentyl)oxy)-4H-chromen-4-one (**25c**): Compound **25c** (60 mg, 27.8%) was synthesized from TsO(CH₂)₅OH (104 mg, 0.4 mmol), according to the procedure used to prepare **25a**, obtained as yellow solid.

2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-5-hydroxy-7-((6-hydroxyhexyl)oxy)-4H-chromen-4-one (**25d**): Compound **25d** (132 mg, 47.5%) was synthesized from TsO(CH₂)₆OH (133 mg, 0.49 mmol), according to the procedure used to prepare **25a**, obtained as yellow solid.

2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-5-hydroxy-7-((8-hydroxyoctyl)oxy)-4H-chromen-4-one (**25e**): Compound **25e** (237 mg, 55.3 %) was synthesized from TsO(CH₂)₈OH (288 mg, 0.96 mmol), according to the procedure used to prepare **25a**, obtained as yellow solid.

2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-5-hydroxy-7-((10-hydroxydecyl)oxy)-4H-chromen-4-one (**25f**): Compound **25f** (212 mg, 49.9%) was synthesized from TsO(CH₂)₁₀OH (340 mg, 1.04 mmol), according to the procedure used to prepare **25a**, obtained as yellow solid.

2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-5-hydroxy-7-(4-hydroxybutoxy)-4H-chromen-4-one (**25b**): HF (743 µL, 17.1 mmol) and pyridine (1.4 mL, 17.1 mmol) were added to a solution of **24** (36 mg, 0.057 mmol) in MeCN (1 mL) at room temperature. After stirring overnight, the reaction was quenched by 1N hydrochloric acid, and extracted with EtOAc. The organic layer was washed with saturated aqueous NaHCO₃ and NaCl successively, dried over Na₂SO₄, filtered, and concentrated in vacuo to give **25b** (24 mg, 80.7%) as yellow solid.

(E)-3-((2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)propyl 3-(4-acetoxyphenyl)acrylate (**26a**): Compound **26a** (34 mg, 24.4%) was synthesized from **25a** (101 mg, 0.2 mmol) according to the procedure used to prepare **17**. The crude product was purified by column chromatography (PE/acetone = 5:1) to give **26a** as yellow solids.

(E)-4-((2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)butyl 3-(4-acetoxyphenyl)acrylate (**26b**): Compound **26b** (19 mg, 58.1%) was synthesized from **25b** (24 mg, 0.046 mmol) according to the procedure used to prepare **17**. The crude product was purified by column chromatography (PE/DCM/acetone = 10:10:1) to give **25b** as yellow solids.

(E)-5-((2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)pentyl 3-(4-acetoxyphenyl)acrylate (**26c**): Compound **26c** (17 mg, 36.1%) was synthesized from **25c** (35 mg, 0.065 mmol) according to the procedure used to prepare **17**. The crude product was purified by column chromatography (PE/DCM/acetone = 10:10:1) to give **26c** as yellow solids.

(E)-6-((2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)hexyl 3-(4-acetoxyphenyl)acrylate (**26d**): Compound **26d** (35 mg, 33.8%) was synthesized from **25d** (75 mg, 0.14 mmol) according to the procedure used to prepare **17**. The crude product was purified by column chromatography (PE/DCM/acetone = 10:10:1) to give **26d** as yellow solids.

(E)-8-((2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)octyl 3-(4-acetoxyphenyl)acrylate (**26e**): Compound **26e** (52 mg, 40.1%) was synthesized from **25e** (100 mg, 0.17 mmol) according to the procedure used to prepare **17**. The crude product was purified by column chromatography (PE/DCM/THF = 20:20:3) to give **26e** as yellow solids.

(E)-10-((2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)decyl 3-(4-acetoxyphenyl)acrylate (**26f**): Compound **26f** (44 mg, 30.7%) was synthesized from **25f** (110 mg, 0.18 mmol) according to the procedure used to prepare **17**. The crude product was purified by column chromatography (PE/DCM/THF = 20:20:3) to give **26f** as yellow solids.

(E)-3-((2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)propyl 3-(4-hydroxyphenyl)acrylate (**5a**): Compound **5a** (12 mg, 48.9%) was synthesized from **26a** (34 mg, 0.05 mmol) according to

the procedure used to prepare **4j**. The crude product was purified by column chromatography (chloroform/methanol = 35:1) to give **5a** as yellow solids.

(*E*)-4-((2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4*H*-chromen-7-yl)oxy)butyl 3-(4-hydroxyphenyl)acrylate (**5b**): Compound **5b** (5.2 mg, 36.8%) was synthesized from **26b** (19 mg, 0.028 mmol), according to the procedure used to prepare **5a**, to give **5b** as yellow solids.

(*E*)-5-((2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4*H*-chromen-7-yl)oxy)pentyl 3-(4-hydroxyphenyl)acrylate, (**5c**): Compound **5c** (5.1 mg, 42.8%) was synthesized from **26c** (17 mg, 0.023 mmol), according to the procedure used to prepare **5a**, to give **5c** as yellow solids.

(*E*)-6-((2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4*H*-chromen-7-yl)oxy)hexyl 3-(4-hydroxyphenyl)acrylate (**5d**): Compound **5d** (6.9 mg, 27.6%) was synthesized from **26d** (35 mg, 0.047 mmol), according to the procedure used to prepare **5a**, to give **5d** as yellow solids.

(*E*)-8-((2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4*H*-chromen-7-yl)oxy)octyl 3-(4-hydroxyphenyl)acrylate (**5e**): Compound **5e** (8.2 mg, 29.3%) was synthesized from **26e** (38 mg, 0.05 mmol), according to the procedure used to prepare **5a**, to give **5e** as yellow solids.

(*E*)-10-((2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4*H*-chromen-7-yl)oxy)decyl 3-(4-hydroxyphenyl)acrylate (**5f**): Compound **5f** (7.3 mg, 27.6%) was synthesized from **26f** (36 mg, 0.045 mmol), according to the procedure used to prepare **5a**, to give **5f** as yellow solids.

3.1.4. Synthesis of Compound **7a–q**

2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-5-hydroxy-7-(2-hydroxyethoxy)-4*H*-chromen-4-one (**27**): Compound **27** (195 mg, 57%) was synthesized from **23** according to the procedure used to prepare **25a**. The crude product was purified by column chromatography (CH₂Cl₂/acetone = 10:1) to give **27** as yellow solids.

2-((2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-5-hydroxy-4-oxo-4*H*-chromen-7-yl)oxy)ethyl cinnamate (**28a**): Compound **28a** (28 mg, 57.6%) was synthesized from **27** (40 mg, 0.08 mmol) and cinnamic acid (35 mg, 0.24 mmol) according to the procedure used to prepare **21**. The crude product was purified by column chromatography (PE/acetone = 5:1) to give **28a** as yellow solids.

(*E*)-2-((2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-5-hydroxy-4-oxo-4*H*-chromen-7-yl)oxy)ethyl 3-(2-acetoxyphenyl)acrylate (**28b**): To a solution of 2-acetoxycinnamic acid (54 mg, 0.26 mmol) in dichloroethane (5 mL), SOCl₂ (100 µL, 2.6 mmol) and DMF (1d) were added. The solution was stirred at 80 °C for 1 h, the organic solvent was removed under vacuum, and the residue dissolved in dry CH₂Cl₂ (4 mL). Pyridine (31 µL, 0.38 mmol) was added at 0 °C, then **27** (64 mg, 0.13 mmol) was added dropwise. The resulting mixture was transferred to r.t. and stirred for 4 h. The organic solvent was washed with 1M hydrochloric acid and brine, dried over Na₂SO₄, filtered, and concentrated in vacuo. The crude product was purified by column chromatography (PE/acetone = 5:1) to give **28b** as yellow solid (58 mg, 50.3%).

(*E*)-2-((2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-5-hydroxy-4-oxo-4*H*-chromen-7-yl)oxy)ethyl 3-(3-acetoxyphenyl)acrylate (**28c**): Compound **28c** (48 mg, 35.2%) was synthesized from **27** (100 mg, 0.2 mmol) and 3-acetoxycinnamic acid (124 mg, 0.6 mmol), according to the procedure used to prepare **21**. The crude product was purified by column chromatography (PE/acetone = 5:1) to give **28c** as yellow solids.

(*E*)-4-(3-(2-((2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-5-hydroxy-4-oxo-4*H*-chromen-7-yl)oxy)ethoxy)-3-oxoprop-1-en-1-yl)-1,2-phenylene diacetate (**28d**): Compound **28d** (24 mg, 46.3%) was synthesized from **27** (35 mg, 0.07 mmol) and 3,4-diacetoxycinnamic acid (28 mg, 0.11 mmol), according to the procedure used to prepare **28b**. The crude product was purified by column chromatography (PE/acetone = 4:1) to give **28d** as yellow solids.

(*E*)-2-((2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-5-hydroxy-4-oxo-4*H*-chromen-7-yl)oxy)ethyl 3-(4-fluorophenyl)acrylate (**28e**): Compound **28e** (37 mg, 44.3%) was synthesized from **27** (64 mg, 0.13 mmol) and 4-fluorocinnamic acid (65 mg, 0.39 mmol), according to the procedure used to prepare **21**. The crude product was purified by column chromatography (PE/acetone = 5:1) to give **28e** as white solids.

(*E*)-2-((2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-5-hydroxy-4-oxo-4*H*-chromen-7-yl)oxy)ethyl 3-(4-chlorophenyl)acrylate (**28f**): Compound **28f** (44 mg, 55.6%) was synthesized from **27** (60 mg, 0.12 mmol) and 4-chlorocinnamic acid (66 mg, 0.36 mmol), according to the procedure used to prepare **21**. The crude product was purified by column chromatography (PE/acetone = 5:1) to give **28f** as yellow solids.

(*E*)-2-((2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-5-hydroxy-4-oxo-4*H*-chromen-7-yl)oxy)ethyl 3-(4-nitrophenyl)acrylate (**28g**): Compound **28g** (34 mg, 55.8%) was synthesized from **27** (45 mg, 0.09 mmol) and 4-nitrocinnamic acid (52 mg, 0.27 mmol), according to the procedure used to prepare **21**. The crude product was purified by column chromatography (PE/acetone = 5:1) to give **28g** as white solids.

(*E*)-2-((2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-5-hydroxy-4-oxo-4*H*-chromen-7-yl)oxy)ethyl 3-(4-(dimethylamino)phenyl)acrylate (**28h**): Compound **28h** (24 mg, 45.1%) was synthesized from **27** (40 mg, 0.08 mmol) and 4-dimethylaminocinnamic acid (46 mg, 0.24 mmol), according to the procedure used to prepare **21**. The crude product was purified by column chromatography (PE/acetone = 5:1) to give **28h** as white solids.

(*E*)-2-((2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-5-hydroxy-4-oxo-4*H*-chromen-7-yl)oxy)ethyl 3-(4-methoxyphenyl)acrylate (**28i**): Compound **28i** (44 mg, 42.1%) was synthesized from **27** (80 mg, 0.16 mmol) and 4-methoxycinnamic acid (86 mg, 0.48 mmol), according to the procedure used to prepare **21**. The crude product was purified by column chromatography (PE/acetone = 5:1) to give **28i** as yellow solids.

(*E*)-2-((2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-5-hydroxy-4-oxo-4*H*-chromen-7-yl)oxy)ethyl 3-(4-(*tert*-butyl)phenyl)acrylate (**28j**): Compound **28j** (31 mg, 48.4%) was synthesized from **27** (51 mg, 0.1 mmol) and 4-*tert*-butylcinnamic acid (61 mg, 0.3 mmol), according to the procedure used to prepare **21**. The crude product was purified by column chromatography (PE/acetone = 5:1) to give **28j** as white solids.

(*E*)-2-((2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-5-hydroxy-4-oxo-4*H*-chromen-7-yl)oxy)ethyl 3-(pyridin-3-yl)acrylate (**28k**): Compound **28k** (63 mg, 63.0%) was synthesized from **27** (80 mg, 0.16 mmol) and (*E*)-3-(pyridin-3-yl)acrylic acid (46 mg, 0.48 mmol), according to the procedure used to prepare **21**. The crude product was purified by column chromatography (PE/acetone = 3:1) to give **28k** as yellow solids.

(*E*)-2-((2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-5-hydroxy-4-oxo-4*H*-chromen-7-yl)oxy)ethyl 3-(furan-3-yl)acrylate (**28l**): Compound **28l** (36 mg, 36.6%) was synthesized from **27** (80 mg, 0.16 mmol) and (*E*)-3-(furan-3-yl)acrylic acid (66 mg, 0.48 mmol), according to the procedure used to prepare **21**. The crude product was purified by column chromatography (PE/acetone = 5:1) to give **28l** as white solids.

(*E*)-2-((2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-5-hydroxy-4-oxo-4*H*-chromen-7-yl)oxy)ethyl 3-cyclohexylacrylate (**28m**): Compound **28m** (43 mg, 42.7%) was synthesized from **27** (80 mg, 0.16 mmol) and (*E*)-3-cyclohexylacrylic acid (74 mg, 0.48 mmol), according to the procedure used to prepare **21**. The crude product was purified by column chromatography (PE/DCM/acetone = 20:20:1) to give **28m** as yellow solids.

(*E*)-2-((2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-5-hydroxy-4-oxo-4*H*-chromen-7-yl)oxy)ethyl 3-(3,5-dimethyl-1*H*-pyrazol-1-yl)acrylate (**28n**): Compound **28n** (42 mg, 81.6%) was synthesized from **27** (41 mg, 0.08 mmol) and 3-(3,5-dimethyl-1*H*-pyrazol-1-yl)propanoic acid (41 mg, 0.24 mmol), according to the

procedure used to prepare **21**. The crude product was purified by column chromatography (PE/acetone = 4:1) to give **28m** as yellow solids.

2-((2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)ethyl 4-acetoxybenzoate (28o): Compound **28o** (24 mg, 53.7%) was synthesized from **27** (31 mg, 0.07 mmol) and 4-hydroxybenzoic acid (29 mg, 0.21 mmol), according to the procedure used to prepare **28b**. The crude product was purified by column chromatography (PE/acetone = 5:1) to give **28o** as yellow solids.

(E)-2-((2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)ethyl 3-(4-acetoxyphenyl)acrylate (28q): Compound **28q** (76 mg, 55.7%) was synthesized from **27** (100 mg, 0.2 mmol) and 4-acetoxycinnamic acid (124 mg, 0.6 mmol), according to the procedure used to prepare **21**. The crude product was purified by column chromatography (PE/acetone = 5:1) to give **28q** as yellow solids.

2-((2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)ethyl cinnamate (7a): **28a** (9 mg, 0.015 mmol) was dissolved in a solution of acetone (0.1 mL) and 38% HCl/AcOH (*v/v* = 1:15, 0.5 mL). The mixture was stirred at room temperature for 20 h. The resulting mixture was poured into ice-water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated in vacuo. The residue was purified by column chromatography (DCM/MeOH = 50:1) to give **7a** as yellow solid (2.4 mg, 32.6%).

(E)-2-((2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)ethyl 3-(2-acetoxyphenyl)acrylate (7b): Compound **7b** (26.7 mg, 75.8%) was synthesized from **28b** (49 mg, 0.072 mmol) according to the procedure used to prepare **7a**, obtained as brown solids.

(E)-2-((2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)ethyl 3-(3-acetoxyphenyl)acrylate (7c): Compound **7c** (12.8 mg, 45.6%) was synthesized from **28c** (40 mg, 0.059 mmol) according to the procedure used to prepare **7a**, obtained as yellow solids.

(E)-4-(3-(2-((2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)ethoxy)-3-oxoprop-1-en-1-yl)-1,2-phenylene diacetate (7d): Compound **7d** (2.2 mg, 37.3%) was synthesized from **28d** (6 mg, 0.012 mmol), according to the procedure used to prepare **7a**. The crude product was purified by column chromatography (DCM/MeOH = 20:1) to give **7d** as white solids.

(E)-2-((2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)ethyl 3-(4-fluorophenyl)acrylate (7e): Compound **7e** (9.3 mg, 62.7%) was synthesized from **28e** (23 mg, 0.031 mmol) according to the procedure used to prepare **7a**, obtained as light-yellow solids.

(E)-2-((2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)ethyl 3-(4-chlorophenyl)acrylate (7f): Compound **7f** (26 mg, 87.7%) was synthesized from **28f** (40 mg, 0.06 mmol) according to the procedure used to prepare **7a** without post process, obtained as white solids.

(E)-2-((2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)ethyl 3-(4-nitrophenyl)acrylate (7g): Compound **7g** (4.1 mg, 63.5%) was synthesized from **28g** (9 mg, 0.013 mmol) according to the procedure used to prepare **7a**, obtained as white solids.

(E)-2-((2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)ethyl 3-(4-(dimethylamino)phenyl)acrylate (7h): Compound **7h** (5.1 mg, 49.7%) was synthesized from **28h** (15 mg, 0.02 mmol) according to the procedure used to prepare **7a**, obtained as yellow solids.

(E)-2-((2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)ethyl 3-(4-methoxyphenyl)acrylate (7i): Compound **7i** (18.8 mg, 57.3%) was synthesized from **28i** (44 mg, 0.067 mmol) according to the procedure used to prepare **7a**, obtained as white solids.

(E)-2-((2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)ethyl 3-(4-(tert-butyl)phenyl)acrylate (7j): Compound **7j** (8.8 mg, 46.3%) was synthesized from **28j** (25 mg, 0.037 mmol) according to the procedure used to prepare **7a**, obtained as white solids.

(*E*)-2-((2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)ethyl 3-(pyridin-3-yl)acrylate (**7k**): Compound **7k** (12 mg, 57.3%) was synthesized from **28k** (20 mg, 0.067 mmol) according to the procedure used to prepare **7a**, obtained as yellow solids.

(*E*)-2-((2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)ethyl 3-(furan-3-yl)acrylate (**7l**): Compound **7l** (4.4 mg, 42.5%) was synthesized from **28l** (14 mg, 0.023 mmol) according to the procedure used to prepare **7a**, obtained as light-yellow solids.

(*E*)-2-((2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)ethyl 3-cyclohexylacrylate (**7m**): Compound **7m** (19.2 mg, 60.6%) was synthesized from **28m** (43 mg, 0.068 mmol) according to the procedure used to prepare **7a**, obtained as white solids.

(*E*)-2-((2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)ethyl 3-(3,5-dimethyl-1H-pyrazol-1-yl)acrylate (**7n**): Compound **7n** (14.2 mg, 59.2%) was synthesized from **28n** (32 mg, 0.05 mmol) according to the procedure used to prepare **7a**, obtained as yellow solids.

2-((2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)ethyl 4-hydroxybenzoate (**7o**): Compound **7o** (5.2 mg, 57.8%) was synthesized from **28o** (12 mg, 0.02 mmol) according to the procedure used to prepare **7a**, obtained as yellow solids.

2-((2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)ethyl 3-(4-hydroxyphenyl)propanoate (**7p**): To a solution of compound **28p** (24 mg, 0.038 mmol) in THF (1 mL) and EtOH (1 mL), 10% Pb/C (16 mg, 0.015 mmol) and 1,4-cyclohexadiene (141 μ L, 1.5 mmol) were added. The solution was stirred reflux for 5 h. The resulting solution was concentrated after filtrating and purified by column chromatography (DCM/MeOH = 40:1) to give **7p** as yellow solid (11 mg, 61.4%).

(*E*)-2-((2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl)oxy)ethyl 3-(4-acetoxyphenyl)acrylate (**7q**): To a solution of compound **28q** (100 mg, 0.15 mmol) in DCM (5 mL), CF₃COOH (0.55 mL, 7.5 mmol) was added. The solution was stirred at room temperature for 12 h. The resulting solution was concentrated and purified by column chromatography (DCM/MeOH = 30:1) to give **7q** as yellow solid (16.7 mg, 31.4%).

3.2. In Vitro BACE1 Enzyme Assay

The BACE1 FRET assay kit was purchased from the PanVera Co. (Invitrogen, USA). The assay was carried out according to the supplied manual with modifications. Briefly, assays were performed in triplicate in 384-well black plates with a mixture of 5 μ L of BACE1 (1.0 U/mL), 5 μ L of the substrate (750 nM, Rh-EVNLDAEFK-Quencherin 50 mM, ammonium bicarbonate), and 5 μ L of compound dissolved in 10% DMSO. The fluorescence intensity was measured with a TECAN infinite 200 microplate reader for 60 min at 25 °C in the dark. The mixture was irradiated at 544 nm and the emission intensity recorded at 590 nm. The percent inhibition (%) was obtained by the following equation: Inhibition % = $(1 - SS/SC) \times 100\%$, where SC is the slope of fluorescence change of the control (enzyme, buffer, and substrate) during 60 min, and SS is the slope of fluorescence change of the tested samples (enzyme, sample solution, and substrate) during 60 min of measurement. IC₅₀ values were calculated from the nonlinear curve fitting of percentage inhibition against inhibitor concentration using Prism 3.0 software (GraphPad Software, San Diego, CA, USA).

3.3. Inhibition of A β Production in APP Overexpressed Cells

HEK293 cells stably overexpressing human APP695 were plated in a poly-D-lysine-coated 96-well plates and grown to a density of 80–90%. Compounds were dissolved in DMSO to make a 10 mM stock solution and diluted in DMEM complete medium to the final concentrations: 0.1, 1.0, 5.0, 10.0, 25.0, and 50.0 μ M. DMSO was used at a 1:200 dilution as a negative control and a commercially available BACE1 inhibitor (C3, also known as BACE inhibitor IV) as a positive control. After 23 h of incubation, the cell supernatants were directly used for measurement in the V-Plex A β Peptide Panel 1 (6E10) Kit

from Meso Scale Diagnostics (Rockville, MD, USA) for measuring A β 38, –40, and –42 simultaneously. Cells were washed with PBS and lysed in Triton X100 lysis buffer for subsequent protein concentration (BCA) measurement.

3.4. Kinetic Analysis

The Dixon plot is a graphical method (plot of $1/\text{enzyme velocity}$ ($1/V$) against inhibitor concentration (I)) for determination of the type of enzyme inhibition, which was used to determine the dissociation or inhibition constant (K_i) for the enzyme inhibitor complex [17]. The Dixon plots for BACE1 inhibition were obtained in the presence of various concentrations of BACE1 substrate (250, 500, 750 nM) and the concentrations of **4l**, **7c**, and **7k** as follows: 0.1 μM , 0.5 μM , 1.0 μM . In this way, the inhibition constants (K_i) of **4e** were determined by interpretation of Dixon plots, where the value of the x -axis represents $-K_i$ when $1/V = 0$.

3.5. MTT Assays

The cytotoxicity was examined by using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT) assay. HEK293T cells were seeded with complete DMEM into 96-well plates (104/well, 100 L/well), incubated at 37 °C in a humidified atmosphere with 5% CO₂ for 24 h. All the compounds were diluted with the phenol red-free DMEM at a specific concentration. After 24 h of exposure to different concentrations of compound, the supernatant was removed and then 20% (v/v) MTT (5 mg/mL) diluted with fresh culture medium was added into each well and incubated for 4 h. Cells were lysed with 100 μL dimethyl sulfoxide (DMSO) and shaken for 10 min at room temperature. The absorbance in each well was detected at a wavelength of 490 nm using a Universal Microplate Reader (ELX 800 Iv, BIO-TEK Instruments, Inc., Winooski, VT, USA).

Supplementary Materials: The following are available online at <http://www.mdpi.com/1420-3049/25/1/102/s1>: Scheme S1. Synthesis of compound **4a–4h**; Scheme S2. Synthesis of compound **4i**; Scheme S3. Synthesis of compound **4k**; Scheme S4. Synthesis of compound **4l**; Scheme S5. Synthesis of compound **5g**; Scheme S6. Synthesis of compound **6**; Scheme S7. Synthesis of compound **8**; Figure S1. The normalized A β 38 level in APP overexpressing HEK293 cells after the treatment of **7a–7d**, **7i**, **7k**, and luteolin compared with DMSO (100%) the known inhibitor C3; Figure S2 The normalized A β 38 level in APP overexpressing HEK293 cells after the treatment of **7a–7d**, **7i**, **7k**, and luteolin compared with DMSO (100%) and the known inhibitor C3; Figure S3 Kinetic analysis of **4l**; Figure S4 Kinetic analysis of **7k**; Figure S5. S-curve for IC₅₀ calculation of compounds **7a**, **7d**, **7p**, **7h**, **7g**, **7k**, and **8**; Table S1. The NMR data and MS data of compounds shown in the text; Table S2. ClogP and BBB level calculation by <http://admet.scbdd.com/>

Author Contributions: D.-Y.S. performed chemical synthesis and some enzyme experiments; C.C. carried out the cytotoxicity test and enzyme selectivity test; K.M. carried out the study of enzyme inhibition activity in cells; writing—original draft preparation, D.-Y.S. and C.C.; writing—review and editing, W.-S.F. and J.H.; W.-S.F. planned, designed, and organized the whole research of this study. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by NSFC, grant nos. 81273406 (W.-S.F.) and 31371331 (J.H.), and by the Drug Innovation Major Project Grant, grant nos. 2018ZX09711001-001-001 and 2018ZX09711001-001-003.

Acknowledgments: The authors cordially thank Stefan Lichtenthaler, Technical University of Munich for his generous support to this work.

Conflicts of Interest: The authors declare no conflict of interest regarding the publication of this paper.

References

1. Silva, T.; Reis, J.; Teixeira, J.C.S.; Borges, F. Alzheimer's disease, enzyme targets and drug discovery struggles: From natural products to drug prototypes. *Ageing. Res. Rev.* **2014**, *15*, 116–145. [CrossRef] [PubMed]
2. Dourlen, P.; Kilinc, D.; Malmanche, N.; Chapuis, J.; Lambert, J.C. The new genetic landscape of Alzheimer's disease: From amyloid cascade to genetically driven synaptic failure hypothesis? *Acta Neuropathol.* **2019**, *138*, 221–236. [CrossRef] [PubMed]
3. Karran, E.; Mercken, M.; De, S.B. The amyloid cascade hypothesis for Alzheimer's disease: An appraisal for the development of therapeutics. *Nat. Rev. Drug. Disc.* **2011**, *10*, 698–712. [CrossRef] [PubMed]

4. Cline, E.; Bicca, M.A.; Viola, K.L.; Klein, W.L. The amyloid- β oligomer hypothesis: Beginning of the third decade. *J. Alzheimers. Dis.* **2018**, *64*, S567–S610. [[CrossRef](#)] [[PubMed](#)]
5. Vassar, R.; Kuhn, P.-H.; Haass, C.; Kennedy, M.E.; Rajendran, L.; Wong, P.C.; Lichtenthaler, S. Function, therapeutic potential and cell biology of BACE proteases: Current status and future prospects. *J. Neurochem.* **2014**, *130*, 4–28. [[CrossRef](#)] [[PubMed](#)]
6. Coimbra, J.R.M.; Marques, D.F.F.; Baptista, S.J.; Pereira, C.M.F.; Moreira, P.I.; Dinis, T.C.P.; Santos, A.E.; Salvador, J.A.R. Highlights in BACE1 inhibitors for Alzheimer's disease treatment. *Front. Chem.* **2018**, *6*, 178–188. [[CrossRef](#)] [[PubMed](#)]
7. Weller, J.; Budson, A. Current understanding of Alzheimer's disease diagnosis and treatment. *F1000Research* **2018**, *7*, 1161–1170. [[CrossRef](#)] [[PubMed](#)]
8. Hu, X.; Das, B.; Hou, H.; He, W.; Yan, R. BACE1 deletion in the adult mouse reverses preformed amyloid deposition and improves cognitive functions. *J. Exp. Med.* **2018**, *3*, 927–940. [[CrossRef](#)] [[PubMed](#)]
9. Keskin, A.D.; Kekuš, M.; Adelsberger, H.; Neumann, U.; Shimshek, D.R.; Song, B.; Zott, B.; Peng, T.; Förstl, H.; Staufenbiel, M.; et al. BACE inhibition-dependent repair of Alzheimer's pathophysiology. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, 8631–8636. [[CrossRef](#)] [[PubMed](#)]
10. Justyna, A.; Zakaria, J.A.D.; Vassar, R.J. A promising, novel, and unique BACE1 inhibitor emerges in the quest to prevent Alzheimer's disease. *EMBO Mol. Med.* **2018**, *10*, 1–3.
11. Morris, G.P.; Clark, I.A.; Vissel, B. Questions concerning the role of amyloid- β in the definition, aetiology and diagnosis of Alzheimer's disease. *Acta. Neuropathol.* **2018**, *136*, 663–689. [[CrossRef](#)] [[PubMed](#)]
12. Williams, P.; Sorribas, A.; Howes, M.J. Natural products as a source of Alzheimer's drug leads. *Nat. Prod. Rep.* **2010**, *28*, 48–77. [[CrossRef](#)] [[PubMed](#)]
13. Fang, W.-S.; Sun, D.-Y.; Yang, S.; Cheng, C.; Moschke, K.; Li, T.Q.; Sun, S.S.; Stefan, L.; Huang, J.; Wang, Y.H. Discovery of a series of selective and cell permeable beta-secretase (BACE1) inhibitors by fragment linking with the assistance of STD-NMR. *Bioorg. Chem.* **2019**, *92*, 1–7. [[CrossRef](#)] [[PubMed](#)]
14. Krishna, N.R.; Jayalakshmi, V. Quantitative analysis of STD-NMR spectra of reversibly forming ligand-receptor complexes. *Top. Curr. Chem.* **2008**, *273*, 15–54. [[PubMed](#)]
15. Stachel, S.J.; Coburn, C.A.; Steele, T.G.; Jones, K.G.; Loutzenhiser, E.F.; Gregro, A.R. Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1). *J. Med. Chem.* **2004**, *47*, 6447–6450. [[CrossRef](#)] [[PubMed](#)]
16. Dong, J.; Wang, N.-N.; Yao, Z.-J.; Zhang, L.; Cheng, Y.; Ouyang, D.F.; Lu, A.-P.; Cao, D.-S. ADMETlab: A platform for systematic ADMET evaluation based on a comprehensively collected ADMET database. *J. Cheminform.* **2018**, *10*, 29–40. [[CrossRef](#)] [[PubMed](#)]
17. Cornish-Bowden, A.; Eisenthal, R. Statistical considerations in the estimation of enzyme kinetic parameters by the Direct Linear Plot and other methods. *Biochem. J.* **1974**, *139*, 721–730. [[CrossRef](#)] [[PubMed](#)]

Sample Availability: Not available.



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).